Very little is known about visual functional recovery following long-term naltrexone administration in opioid-dependent patients. In the present study, a portable event-related potential (ERP) working system was uti...Very little is known about visual functional recovery following long-term naltrexone administration in opioid-dependent patients. In the present study, a portable event-related potential (ERP) working system was utilized to collect and record ERP in opioid-dependent patients and normal controls in visual half-field testing. In addition, the influence of long-term sustained naltrexone release on the visual nervous system was observed in opioid-dependent patients. Results revealed a significant main group effect in reaction time to visual signal stimulations. The reaction time of normal controls was shortest, but longest in opioid-dependent patients. The reaction time of long-term sustained naltrexone release group and compulsory detoxification group was similar to normal controls. A significant main group effect was also observed in P100 latency, and P100 latency in normal controls and the compulsory detoxification group was significantly decreased compared with the opioid-dependent patients. P100 amplitude at the Oz-electrode resulted in a significant main group effect. In particular, normal controls exhibited significant differences compared with long-term sustained release naltrexone and compulsory detoxification groups. These findings demonstrated that long-term sustained naltrexone release effectively ameliorated optic center function and improved visual sensitivity and reactions in opioid-dependent patients.展开更多
Oral methadone or sublingual buprenorphine are first-line medications for pharmacotherapy of opioid use disorders(OUDs).Three long-acting buprenorphine depot or implant formulations are currently available for the tre...Oral methadone or sublingual buprenorphine are first-line medications for pharmacotherapy of opioid use disorders(OUDs).Three long-acting buprenorphine depot or implant formulations are currently available for the treatment of OUDs:(1)CAM 2038(Buvidal)for subcutaneous weekly and monthly application;(2)RBP-6000(Sublocade^(TM))as a monthly depot formulation;and(3)A six-month buprenorphine implant[Probuphine^(TM)].The pharmacology,clinical efficacy and prospects of these medications are discussed.展开更多
OBJECTIVE:To investigate the effect of Yiguanjian(YGJ) cataplasm on the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome.METHODS:One hundred Swiss albino mice,of equal m...OBJECTIVE:To investigate the effect of Yiguanjian(YGJ) cataplasm on the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome.METHODS:One hundred Swiss albino mice,of equal male to female ratio,were randomly and equally divided into 10 groups.A portion(3 cm2) of the backside hair of the mice was removed 1 day prior to the experiment.Morphine(5 mg/kg) was intraperitoneally administered twice daily for 5days.YGJ cataplasm was prepared and pasted on the bare region of the mice immediately beforemorphine administration on day 3 and subsequently removed at the end day 5.On day 6,naloxone(8mg/kg) was intraperitoneally injected to precipitate opioid withdrawal syndrome.Behavioral observation was performed in two 30-min phases immediately after naloxone injection.RESULTS:The YGJ cataplasm significantly and dose-dependently attenuated morphine-naloxone-induced experimental opioid withdrawal,in terms of withdrawal severity score and the frequencies of jumping,rearing,forepaw licking,and circling behaviors.However,YGJ cataplasm treatment did not alter the acute analgesic effect of morphine.CONCLUSION:YGJ cataplasm could attenuate opioid dependence and its associated withdrawal symptoms.Therefore,YGJ cataplasm could serve as a potential therapy for opioid addiction in the future.展开更多
基金the Natural Science Foundation of Guangdong Province,No. 06027973the Science and Technology Development Program of Guangdong Province,No. 2004B3600105the Medical Science Foundation Program of Guangdong Province,No. A2007592
文摘Very little is known about visual functional recovery following long-term naltrexone administration in opioid-dependent patients. In the present study, a portable event-related potential (ERP) working system was utilized to collect and record ERP in opioid-dependent patients and normal controls in visual half-field testing. In addition, the influence of long-term sustained naltrexone release on the visual nervous system was observed in opioid-dependent patients. Results revealed a significant main group effect in reaction time to visual signal stimulations. The reaction time of normal controls was shortest, but longest in opioid-dependent patients. The reaction time of long-term sustained naltrexone release group and compulsory detoxification group was similar to normal controls. A significant main group effect was also observed in P100 latency, and P100 latency in normal controls and the compulsory detoxification group was significantly decreased compared with the opioid-dependent patients. P100 amplitude at the Oz-electrode resulted in a significant main group effect. In particular, normal controls exhibited significant differences compared with long-term sustained release naltrexone and compulsory detoxification groups. These findings demonstrated that long-term sustained naltrexone release effectively ameliorated optic center function and improved visual sensitivity and reactions in opioid-dependent patients.
文摘Oral methadone or sublingual buprenorphine are first-line medications for pharmacotherapy of opioid use disorders(OUDs).Three long-acting buprenorphine depot or implant formulations are currently available for the treatment of OUDs:(1)CAM 2038(Buvidal)for subcutaneous weekly and monthly application;(2)RBP-6000(Sublocade^(TM))as a monthly depot formulation;and(3)A six-month buprenorphine implant[Probuphine^(TM)].The pharmacology,clinical efficacy and prospects of these medications are discussed.
基金Supported by Shandong Foundation for Development of Science and Technology,China(Research and Development of Umbilical Treatment Cataplasm for Drug Rehabilitation,No.2009GG10008007)
文摘OBJECTIVE:To investigate the effect of Yiguanjian(YGJ) cataplasm on the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome.METHODS:One hundred Swiss albino mice,of equal male to female ratio,were randomly and equally divided into 10 groups.A portion(3 cm2) of the backside hair of the mice was removed 1 day prior to the experiment.Morphine(5 mg/kg) was intraperitoneally administered twice daily for 5days.YGJ cataplasm was prepared and pasted on the bare region of the mice immediately beforemorphine administration on day 3 and subsequently removed at the end day 5.On day 6,naloxone(8mg/kg) was intraperitoneally injected to precipitate opioid withdrawal syndrome.Behavioral observation was performed in two 30-min phases immediately after naloxone injection.RESULTS:The YGJ cataplasm significantly and dose-dependently attenuated morphine-naloxone-induced experimental opioid withdrawal,in terms of withdrawal severity score and the frequencies of jumping,rearing,forepaw licking,and circling behaviors.However,YGJ cataplasm treatment did not alter the acute analgesic effect of morphine.CONCLUSION:YGJ cataplasm could attenuate opioid dependence and its associated withdrawal symptoms.Therefore,YGJ cataplasm could serve as a potential therapy for opioid addiction in the future.